MARKET NEWS

Nadroparin calcium launched in Canada

The low molecular weight heparin nadroparin calcium [‘Fraxiparine’; Sanofi] has been launched in Canada.

Nadroparin calcium is indicated for use in the prevention of venous thromboembolism in patients undergoing general and orthopaedic surgery, for the treatment of deep vein thrombosis and for use in haemodialysis.

Mr Yvon Bastien, president of Sanofi, commented that for the average patient, nadroparin calcium ‘will be the most cost-effective low-molecular-weight heparin on the market’.